Clinical Research Directory
Browse clinical research sites, groups, and studies.
Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke
Sponsor: Ospedali Riuniti Trieste
Summary
Acute ischemic stroke is caused by reduced blood supply to the brain associated with neuroinflammation. This mechanism contributes to acute neuronal death and persists even after reopening of the closed vessel, with consequent limitation of clinical and functional improvement. Experimental and clinical evidence demonstrated the anti-inflammatory and neuroprotective effect of micronized and ultramicronized Palmitoylethanolamide (PEA). The aim of this study is to evaluate the effect of co-ultramicronized PEA and luteolin (700 mg + 70 mg in 10 ml) on the clinical outcomes of patients with acute ischemic stroke undergoing mechanical thrombectomy.
Official title: Efficacy of Palmitoylethanolamide and Luteolin on Early Functional Recovery in Acute Stroke Patients Treated with Thrombectomy: a Pilot Randomized Placebo-controlled Prospective Study
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-01
Completion Date
2026-12
Last Updated
2025-01-16
Healthy Volunteers
No
Conditions
Interventions
co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)
oral suspension, 10 ml twice a day (every 12 hours) for 7 days
Placebo
oral suspension,10 ml twice a day (every 12 hours) for 7 days
Thrombectomy
Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
Locations (1)
Azienda Sanitaria Universitaria Giuliano Isontina
Trieste, Italy, Italy